Stage
No active trials
Next date
None yet
Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months”In the company’s words, NCT04745299 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis (2 trials)
- Main trialPhase 3
- “ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.”In the company’s words, NCT04745299 on ClinicalTrials.gov
- Other names
- Neuronata-R · Neuronata-R inj
Other drugs for Amyotrophic Lateral Sclerosis
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 3 Oct 2024 | Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | |
| Phase 1Completed | 27 Nov 2023 | Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS | |
| Phase 2Authorised | not given | Efficacy of autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. A randomized, controlled, open-label, multi-centre clinical trial. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026